Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Children With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
NCT01362803Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2011
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by National Cancer Institute. Started Sep 2011; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT01362803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362803.